How would you treat a patient with squamous NSCLC with NRG1 amplification (no fusion) who has progressed on first-line treatment?

NRG1 amplification may be associated with NRG1 fusions, but can also occur without fusion. The occurrence is rare and therapeutic outcomes have not been described in the same way as they have been with NRG1 fusion. Given the differing mechanisms and unclear therapeutic benefit, I would not use afati...

Zenocutuzumab appears to be tumor agnostic per early data.